Point72 Asset Management
MDGL icon

Point72 Asset Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Point72 Asset Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.57M Sell
4,900
-400
-8% -$191K ﹤0.01% 2144
2025
Q4 		$3.09M Buy
+5,300
New +$2.71M ﹤0.01% 2182

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management's MDGL Position: Q1 2026 in Review

Point72 Asset Management increased its Madrigal Pharmaceuticals (MDGL) stake by 78% in Q1 2026, buying an estimated $47.3M and bringing the position to 225,510 shares worth $118M. The position accounts for 0.15% of the portfolio, ranked #139.

Point72 Asset Management first reported a position in MDGL in Q4 2017 and has held it in 19 quarters since. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Point72 Asset Management held 225,510 shares of Madrigal Pharmaceuticals worth $118M as of Q1 2026.
  • Point72 Asset Management bought 99,075 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $47.3M.
  • Madrigal Pharmaceuticals made up 0.15% of Point72 Asset Management's portfolio in Q1 2026, its #139 holding.
  • Point72 Asset Management first reported a position in Madrigal Pharmaceuticals in Q4 2017 and has held it in 19 quarters since.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.